AmpliPhi Announces Appointment of New Board Member

  AmpliPhi Announces Appointment of New Board Member

Business Wire

RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY -- May 22, 2014

AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the
development of bacteriophage-based antibacterial therapies to treat drug
resistant infections, announced today that Wendy Johnson has been appointed to
its Board of Directors effective May 19, 2014. Ms. Johnson will stand for
election to the Board along with AmpliPhi’s other Class 2 directors at the
Company’s Annual Meeting on June 27, 2014.

Ms. Johnson brings a broad range of experience in the regulatory and
pharmaceutical industry. Most recently Ms. Johnson was a venture partner at
ProQuest Investments, a venture capital firm, and she served as CEO of Aires
Pharmaceuticals, a ProQuest portfolio company which was recently acquired by
Mast Therapeutics. Prior to joining ProQuest in 2005, Ms. Johnson held a
number of senior corporate development positions at leading pharmaceutical
companies including Salmedix, WomenFirst Healthcare and Prizm Pharmaceuticals.
Prior to entering industry, Ms. Johnson served as Assistant Director with the
Center for Devices and Radiological Health at the U.S. Food and Drug
Administration.

Ms. Johnson holds a Master of Business Administration from Loyola University,
a Masters of Science in clinical microbiology from the Hahnemann Medical
School and a Bachelor of Science in microbiology from the University of
Maryland.

“We are very pleased to have Wendy join our Board,” stated Phil Young,
AmpliPhi President and Chief Executive Officer. “Her many years of industry
experience will be a valuable addition to AmpliPhi as we to continue on our
mission to be a leader in developing novel antibacterial treatments.”

About AmpliPhi BioSciences

AmpliPhi BioSciences Corporation (OTCBB: APHB) is a biotechnology company
focused on the development and commercialization of novel bacteriophage-based
antibacterial therapeutics. The Company's product development programs target
infections that are often resistant to existing antibiotic treatments.
AmpliPhi is collaborating with a number of leading organizations, including
Intrexon Corporation (NYSE: XON), the U.S. Army and UK-based University of
Leicester, to rapidly advance bacteriophage-based therapies. The Company is
US-headquartered in Richmond, Virginia and has operations in Ljubljana,
Slovenia and Sydney, Australia. For more information, visit
www.ampliphibio.com.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific for the
bacterial hosts they infect. They can rapidly kill their host, amplifying
themselves in the process. Bacteriophage are unaffected by antibiotic
resistance and are able to disrupt bacterial biofilms. Such biofilms are a
major line of defence for bacteria, contributing to antibiotic resistance.
Bacteriophage are able to penetrate biofilms and replicate locally to high
levels, to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release regarding AmpliPhi’s bacteriophage product
candidates and their ability to treat infection, including antibiotic
resistant bacterial infections, are forward-looking and are subject to a
number of risks and uncertainties that could cause actual results to differ
materially from the statements made, including without limitation the risk
that bacteriophage-based therapies may not be successfully developed, will
require extensive and expensive pre-clinical and clinical testing, may not be
safe or efficacious, and may not be approved for marketing by the United
States Food and Drug Administration or any foreign regulatory agency. These
risks and uncertainties also include the risks discussed in the “Business,”
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” sections of the Company’s Annual Report
on Form 10-K for the year ended December 31, 2013. The Company does not
undertake any obligation to update any forward-looking statements to reflect
future events or circumstances after the date of such statements.

Contact:

Investor and Media Contact:
AmpliPhi BioSciences Corporation
Baxter Phillips III, +1-804-754-5442
Vice President, Corporate Strategy and Business Development
bfp@ampliphibio.com
 
Press spacebar to pause and continue. Press esc to stop.